Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

(2017) J R Brown et al.   LEUKEMIA

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL--Letter

(2016) A. Zucchetto et al.   CLINICAL CANCER RESEARCH

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

(2016) M. Winqvist et al.   HAEMATOLOGICA

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia

(2016) Elisa ten Hacken et al.   JOURNAL OF IMMUNOLOGY

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia

(2016) M Dal Bo et al.   LEUKEMIA

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

(2016) M. Winqvist et al.   HAEMATOLOGICA

Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy

(2015) M. F. M. de Rooij et al.   BLOOD

Hypermorphic mutation of phospholipase C,  2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

(2015) T.-M. Liu et al.   BLOOD

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

(2015) Philip A. Thompson et al.   CANCER

Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo

(2015) S. E. M. Herman et al.   CLINICAL CANCER RESEARCH

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia

(2015) M. F. M. de Rooij et al.   HAEMATOLOGICA

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

(2015) A. Wiestner   HAEMATOLOGICA

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

(2015) Mohammed Z H Farooqui et al.   LANCET ONCOLOGY

BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia

(2015) S-S Chen et al.   LEUKEMIA

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21

(2015) Sylvia Ganghammer et al.   Oncotarget

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia

(2015) M. F. M. de Rooij et al.   HAEMATOLOGICA

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

(2015) A. Wiestner   HAEMATOLOGICA

How will B-cell-receptor-targeted therapies change future CLL therapy?

(2014) J. A. Jones et al.   BLOOD

Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

(2014) S. E. M. Herman et al.   BLOOD

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

(2014) J. A. Woyach et al.   BLOOD

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia

(2014) Philip A. Thompson et al.   BRITISH JOURNAL OF HAEMATOLOGY

CD49d Is the Strongest Flow Cytometry–Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia

(2014) Pietro Bulian et al.   JOURNAL OF CLINICAL ONCOLOGY

Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician

(2014) John C. Byrd et al.   JOURNAL OF CLINICAL ONCOLOGY

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

(2014) S E M Herman et al.   LEUKEMIA

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma

(2014) A. Wiestner   Hematology-American Society of Hematology Education Program

Targeting B-cell anergy in chronic lymphocytic leukemia

(2013) B. Apollonio et al.   BLOOD

CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism

(2013) A. Zucchetto et al.   BLOOD

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

B cell receptor signaling in chronic lymphocytic leukemia

(2013) Jan A. Burger et al.   TRENDS IN IMMUNOLOGY

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

(2012) D. Rossi et al.   BLOOD

The B-cell receptor signaling pathway as a therapeutic target in CLL

(2012) J. A. Woyach et al.   BLOOD

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

(2012) H. Thorvaldsdottir et al.   BRIEFINGS IN BIOINFORMATICS

The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells

(2012) A Zucchetto et al.   LEUKEMIA

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

(2012) Marcus Dühren-von Minden et al.   NATURE

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

Unknown

(2011) Carlo Calissano et al.   MOLECULAR MEDICINE

A phase I, dose escalation study of lapatinib in combination with carboplatin, paclitaxel, with and without trastuzumab in patients with metastatic breast cancer.

(2010) A Storniolo et al.   CANCER RESEARCH

Real-time Analysis of Conformation-sensitive Antibody Binding Provides New Insights into Integrin Conformational Regulation

(2009) Alexandre Chigaev et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

(2008) Tait D. Shanafelt et al.   BRITISH JOURNAL OF HAEMATOLOGY

Activation of the Small GTPase Rac2 via the B Cell Receptor Regulates B Cell Adhesion and Immunological-Synapse Formation

(2008) Eloisa Arana et al.   IMMUNITY

Regulation of integrin activation through the B-cell receptor

(2008) E. Arana et al.   JOURNAL OF CELL SCIENCE

Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia

(2007) V. Gattei et al.   BLOOD